Translating Human Pharma Science into Animal Health Innovation Translating Human Pharma Science into Animal Health Innovation Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health
collaboration criving innovation collaboration criving innovation In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Boehringer Ingelheim strong growth pipeline acceleration 2023 Boehringer Ingelheim strong growth pipeline acceleration 2023 Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
BTD for GlyT1 in Schizophrenia BTD for GlyT1 in Schizophrenia Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
Circular economy: Taking action to reduce plastic waste Circular economy: Taking action to reduce plastic waste The packaging department team at Yamagata, Japan, managed to reduce their waste plastic material for a greener and more sustainable tomorrow
1948-1990: Going global 1948-1990: Going global The Boehringer Ingelheim history from 1948-1990, with milestones
Phase II trial results in people living with obesity or overweight Phase II trial results in people living with obesity or overweight Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
New indications NexGard, NexGard SPECTRA and Broadline New indications NexGard, NexGard SPECTRA and Broadline New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA